BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31837926)

  • 1. [Percutaneous MR-guided prostate cancer cryoablation: Predictive factors and oncologic outcomes].
    Gaullier M; Tricard T; Garnon J; Cazzato RL; Munier P; De Marini P; Werle P; Lindner V; Gangi A; Lang H
    Prog Urol; 2020 Jan; 30(1):12-18. PubMed ID: 31837926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes.
    Overduin CG; Jenniskens SFM; Sedelaar JPM; Bomers JGR; Fütterer JJ
    Eur Radiol; 2017 Nov; 27(11):4828-4836. PubMed ID: 28409355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.
    De Marini P; Cazzato RL; Garnon J; Tricard T; Koch G; Tsoumakidou G; Ramamurthy N; Lang H; Gangi A
    Br J Radiol; 2019 May; 92(1097):20180965. PubMed ID: 30845821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
    Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
    Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
    Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
    Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
    J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System.
    Safavy S; Jabaji RB; Lu SM; Slezak JM; Cosmatos HA; Williams SG; Finley DS
    Perm J; 2019; 23():. PubMed ID: 31050644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.
    Aminsharifi A; Jibara G; Tsivian E; Tsivian M; Elshafei A; Polascik TJ
    Clin Genitourin Cancer; 2019 Aug; 17(4):e831-e836. PubMed ID: 31213413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation.
    Burton S; Brown DM; Colonias A; Cohen J; Miller R; Rooker G; Benoit R; Merlotti L; Quinn A; Kalnicki S
    Urology; 2000 Nov; 56(5):833-8. PubMed ID: 11068312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
    Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
    BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging.
    Sze C; Tsivian E; Tay KJ; Schulman AA; Davis LG; Gupta RT; Polascik TJ
    BMC Urol; 2019 Dec; 19(1):127. PubMed ID: 31805908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
    Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
    Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience.
    Woodrum DA; Kawashima A; Karnes RJ; Davis BJ; Frank I; Engen DE; Gorny KR; Felmlee JP; Callstrom MR; Mynderse LA
    Urology; 2013 Oct; 82(4):870-5. PubMed ID: 23910089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous MR-guided cryoablation of prostate cancer: initial experience.
    Gangi A; Tsoumakidou G; Abdelli O; Buy X; de Mathelin M; Jacqmin D; Lang H
    Eur Radiol; 2012 Aug; 22(8):1829-35. PubMed ID: 22752525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate.
    Pitman M; Shapiro EY; Hruby GW; Truesdale MD; Cheetham PJ; Saad S; Katz AE
    Prostate; 2012 Dec; 72(16):1802-8. PubMed ID: 22618738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.
    Siddiqui SA; Mynderse LA; Zincke H; Hoffmann NE; Lobo JR; Wilson TM; Kawashima A; Davis BJ; Blute ML
    Urology; 2007 Jul; 70(1):80-5. PubMed ID: 17656213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease.
    Baskin A; Charondo LB; Balakrishnan A; Cowan JE; Cooperberg MR; Carroll PR; Nguyen H; Shinohara K
    Urol Oncol; 2022 Oct; 40(10):451.e15-451.e20. PubMed ID: 35851186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence.
    De La Taille A; Benson MC; Bagiella E; Burchardt M; Shabsigh A; Olsson CA; Katz AE
    BJU Int; 2000 Feb; 85(3):281-6. PubMed ID: 10671882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.